Valuation: Pulse Biosciences, Inc.

Capitalization 937M 801M 744M 698M 1.29B 85.85B 1.39B 8.54B 3.38B 40.57B 3.51B 3.44B 148B P/E ratio 2025 *
-12.1x
P/E ratio 2026 * -8.33x
Enterprise value 937M 801M 744M 698M 1.29B 85.85B 1.39B 8.54B 3.38B 40.57B 3.51B 3.44B 148B EV / Sales 2025 *
2,789x
EV / Sales 2026 * 250x
Free-Float
28.07%
Yield 2025 *
-
Yield 2026 * -
More valuation ratios * Estimated data
Dynamic Chart
1 day+3.83%
1 week+1.48%
Current month+4.59%
1 month-5.90%
3 months-21.14%
6 months-4.90%
Current year+4.59%
More quotes
1 week 13.82
Extreme 13.82
14.79
1 month 13.17
Extreme 13.17
15.96
Current year 13.17
Extreme 13.17
15.64
1 year 12.56
Extreme 12.56
25
3 years 2.36
Extreme 2.36
25
5 years 1.18
Extreme 1.18
45.82
10 years 1.18
Extreme 1.18
45.82
More quotes
Manager TitleAgeSince
Chief Executive Officer 68 08/01/2025
Chief Tech/Sci/R&D Officer - 31/10/2015
Chief Tech/Sci/R&D Officer - 02/05/2023
Director TitleAgeSince
Director/Board Member 60 14/09/2015
Director/Board Member 54 09/02/2017
Chairman 81 01/11/2017
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
+3.83%+1.48%-18.46%+403.86% 937M
+2.79%+4.81%+13.70%+7.18% 233B
-0.71%-6.79%-11.63%+103.95% 187B
+3.29%+2.76%+1.55%-11.79% 166B
+0.56%-2.58%-7.04%+101.03% 135B
-2.00%-6.65%-16.26%-9.37% 58.28B
+2.01%+1.55%+22.01%+7.38% 48.43B
+2.90%-4.48%-5.15%-10.36% 38.51B
+2.41%+1.81%+8.13%+10.46% 36.88B
+2.88%-4.33%-4.30%+21.46% 35.91B
Average +2.18%-2.29%-1.74%+62.38% 93.93B
Weighted average by Cap. +1.92%-1.80%+0.39%+35.95%
See all sector performances

Financials

2025 *2026 *
Net sales 336K 287K 267K 250K 464K 30.78M 497K 3.06M 1.21M 14.55M 1.26M 1.23M 53.13M 3.75M 3.21M 2.98M 2.79M 5.18M 343M 5.55M 34.16M 13.52M 162M 14.06M 13.77M 593M
Net income -76.7M -65.58M -60.88M -57.09M -106M -7.03B -113M -699M -276M -3.32B -288M -282M -12.13B -113M -96.31M -89.4M -83.85M -156M -10.32B -167M -1.03B -406M -4.88B -422M -414M -17.81B
Net Debt - -
More financial data * Estimated data
Logo Pulse Biosciences, Inc.
Pulse Biosciences, Inc. is a bioelectric medicine company. The Company’s proprietary CellFX nsPFA technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is engaged in the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers. The Company’s Nano-pulse Stimulation (NPS) technology is an energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. The Company has designed a variety of applicators, or end-effectors, to explore the potential use of the CellFX platform to treat disorders in other medical specialties, such as cardiology, gastroenterology, gynecology, and ear, nose, and throat.
Employees
75
More about the company
Date Price Change Volume
21/01/26 14.36 $ +3.83% 113,631
20/01/26 13.83 $ -2.95% 93,816
16/01/26 14.25 $ +1.06% 135,917
15/01/26 14.10 $ -1.40% 218,252
14/01/26 14.30 $ +1.06% 141,701

Delayed Quote Nasdaq, January 21, 2026 at 09:00 pm

More quotes
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
13.83USD
Average target price
22.00USD
Spread / Average Target
+59.07%
Consensus

Quarterly revenue - Rate of surprise